Inhaled plasma-derived protein augmentationKamada
Inhaled alpha-1 antitrypsin
Inhaled alpha-1 antitrypsin delivers the protective protease inhibitor directly to the lungs. Kamada developed it to slow lung damage in alpha-1 antitrypsin deficiency.
Also known as: inhaled AAT, Kamada inhaled AAT
1
Trials tracked
0
Resolved
1
Indications
1
Targets
Inhaled alpha-1 antitrypsin forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Inhaled alpha-1 antitrypsin
What is Inhaled alpha-1 antitrypsin?
Inhaled alpha-1 antitrypsin delivers the protective protease inhibitor directly to the lungs. Kamada developed it to slow lung damage in alpha-1 antitrypsin deficiency. It is a inhaled plasma-derived protein augmentation developed by Kamada.
What does Inhaled alpha-1 antitrypsin target?
Inhaled alpha-1 antitrypsin acts on Alpha-1 antitrypsin (SERPINA1).
How well do AI models predict Inhaled alpha-1 antitrypsin trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.